Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

26.26€

-0.3 / -1.13%

2026-10-29 17:36 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

35,907,508
(March 31, 2026)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Leerink Partners

Marc Goodman

Evercore

Michael DiFiore

Jefferies

Shan Hama

Oppenheimer & Co.

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Stifel

Damien Choplain

Truist Securities

Degroof Petercam

David Seynnaeve

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Jean-Pierre Tabart

Documentation

October 2026

Investor Presentation

2026

CSR Report

Latest news

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
October 14, 2026

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
October 13, 2026

Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm
October 9, 2026

Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm

Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
October 9, 2026

Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Medincell announces the temporary suspension of trading in its shares on Euronext Paris
October 9, 2026

Medincell announces the temporary suspension of trading in its shares on Euronext Paris

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau
& Gaëlle Fromaigeat

Newcap